Literature DB >> 1689917

Production of human immunodeficiency virus (HIV)-like particles from cells infected with recombinant vaccinia viruses carrying the gag gene of HIV.

T Shioda1, H Shibuta.   

Abstract

We constructed a recombinant vaccinia virus carrying the entire gag and pol genes of human immunodeficiency virus type 1 (HIV-1). The main gene product detected in the lysates of infected CV-1 and SW480 cells was the gag precursor protein. However, in the culture fluid of infected SW480 cells, but not of infected CV-1 cells, reverse transcriptase (RT) activity was detected. The highest RT activity was found at a density of 1.15 g/ml and this fraction contained many round particles with diameters of 100-150 nm. In contrast to the infected cell lysates, the particles contained the processed gag and pol proteins, suggesting that particle formation may be a prerequisite for efficient processing of the gag precursor by the HIV protease encoded in the pol gene. Particles were also recovered from the culture fluid of SW480 cells infected with another recombinant vaccinia virus carrying only the gag gene. These particles contained the unprocessed gag precursor, indicating that the gag precursor alone was sufficient for particle production.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689917     DOI: 10.1016/0042-6822(90)90194-v

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  48 in total

1.  An endoplasmic reticulum retrieval signal partitions human foamy virus maturation to intracytoplasmic membranes.

Authors:  P A Goepfert; K Shaw; G Wang; A Bansal; B H Edwards; M J Mulligan
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  Activation of HIV-1-specific immune responses to an HIV-1 vaccine constructed from a replication-defective adenovirus vector using various combinations of immunization protocols.

Authors:  T Yoshida; K Okuda; K Q Xin; K Tadokoro; J Fukushima; S Toda; E Hagiwara; K Hamajima; T Koshino; T Saito
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

3.  Mutation of the dominant endocytosis motif in human immunodeficiency virus type 1 gp41 can complement matrix mutations without increasing Env incorporation.

Authors:  John T West; Sally K Weldon; Stephanie Wyss; Xiaoxu Lin; Qin Yu; Markus Thali; Eric Hunter
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

4.  Defective retroviruses can disperse in the human genome by intracellular transposition.

Authors:  T Tchenio; T Heidmann
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

5.  Human immunodeficiency virus envelope protein determines the site of virus release in polarized epithelial cells.

Authors:  R J Owens; J W Dubay; E Hunter; R W Compans
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

6.  The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions.

Authors:  X Yu; X Yuan; Z Matsuda; T H Lee; M Essex
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

7.  Myristylation of Rous sarcoma virus Gag protein does not prevent replication in avian cells.

Authors:  C R Erdie; J W Wills
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

8.  The conserved carboxy terminus of the capsid domain of human immunodeficiency virus type 1 gag protein is important for virion assembly and release.

Authors:  Daniel Melamed; Michal Mark-Danieli; Michal Kenan-Eichler; Osnat Kraus; Asher Castiel; Nihay Laham; Tal Pupko; Fabian Glaser; Nir Ben-Tal; Eran Bacharach
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

9.  Assembly, processing, and infectivity of human immunodeficiency virus type 1 gag mutants.

Authors:  C T Wang; E Barklis
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

10.  Release of virus-like particles from cells infected with poliovirus replicons which express human immunodeficiency virus type 1 Gag.

Authors:  D C Porter; L R Melsen; R W Compans; C D Morrow
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.